Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rESWT vs Botulinum Toxin Type A for Spasticity in CP
NCT02400619Phase 1Completed
- Start
- Sep 2014
- Primary completion
- Jun 2015
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial (2 arms). Primary endpoint: Passive Range of Motion of the foot at 6 months. Started Sep 2014; status: completed.
Beyond the preview
Go deeper on NCT02400619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02400619.